The widespread use of Azithromycin to treat hospitalized patients during the COVID-19 pandemic increased the risk of antimicrobial resistance -- a major global health problem, according to a new study, published in the journal Nature Microbiology. Scientists at the University of California-San Francisco (UCSF) noted that using azithromycin inappropriately for even a single day can trigger antibiotic resistance in the respiratory tract. While azithromycin is effective against bacterial infections that cause strep throat, pneumonia, and sexually transmitted diseases, it does not work against viruses. "We've known for years that antibiotics don't treat viral infections, but these results were striking," said Chaz Langelier, from UCSF. "That we could see resistance genes turning on in the respiratory tract within a day tells us the consequences of unnecessary antibiotic use aren't theoretical or long-term. They're immediate, measurable, and biologically real," Langelier added. The study analyzed nasal swabs of 1,164 adults hospitalized for COVID-19 to examine the changes that occurred in the microbiome of hospitalized patients who were treated for COVID. Compared to people who received no antibiotics, patients administered azithromycin reported changes that persisted for more than a week. These include: Changes in the mix of microbes in the upper airway Decrease in harmless bacteria,Surge in potentially harmful bacteria such as Staphylococcus and Klebsiella.Importantly, the changes “did not go back to baseline and recover after a week,” Langelier was quoted as saying to CIDRAP News. “It really suggests that even a small amount of exposure has measurable biological consequences.” Rising Global Antimicrobial Resistance Antimicrobial resistance (AMR) occurs when germs develop the ability to defeat the drugs designed to kill them. It is one of the 10 top global health threats, undermining the effectiveness of essential treatments and placing millions at risk of untreatable infections. As per WHO data, AMR is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019. In the US alone, more than 2.8 million antimicrobial-resistant infections occur each year. More than 35,000 people die as a result, according to the CDC's 2019 Antibiotic Resistance (AR) Threats Report. The WHO, in a 2025 report, noted that one in six laboratory-confirmed bacterial infections causing common infections in people worldwide in 2023 were resistant to antibiotic treatments. Between 2018 and 2023, antibiotic resistance rose in over 40 percent of the monitored antibiotics with an average annual increase of 5-15 percent. US Early Death Toll During COVID Much Higher About 16 per cent of COVID-19 deaths went uncounted early in the pandemic in the US, according to a separate study, published by the journal Science Advances. While about 840,000 COVID deaths were reported on death certificates in 2020 and 2021, the researchers using artificial intelligence (AI) decoded that as many as 155,000 unrecognised additional deaths likely occurred in that time outside of hospitals.